Drug Profile
Etokimab - AnaptysBio
Alternative Names: ANB-020; Anti-IL33-antibody-AnaptysBio; Anti-interleukin-33-antibody-AnaptysBioLatest Information Update: 31 Jan 2023
Price :
$50
*
At a glance
- Originator AnaptysBio
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibodies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-33 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Respiratory tract disorders
- Discontinued Asthma; Atopic dermatitis; Peanut hypersensitivity; Rhinosinusitis
Most Recent Events
- 31 Jan 2023 AnaptysBio pipeline, January 2023: updated Intro, KDM, Indication, DevT & added relevant HE
- 31 Jan 2023 Phase-I clinical trials in Respiratory tract disorders in USA (Parenteral) before January 2023 (AnaptysBio pipeline, January 2023)
- 31 Jan 2023 AnaptysBio plans a phase IIb/III trial for Respiratory tract disorders in USA (Parenteral) (AnaptysBio pipeline, January 2023)